EHA Roundtable | Professor Xiaohui Zhang’s Team Wins YoungEHA Best Abstract Award: Comprehensive Analysis of Outstanding Research Results

EHA Roundtable | Professor Xiaohui Zhang’s Team Wins YoungEHA Best Abstract Award: Comprehensive Analysis of Outstanding Research Results

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13-16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology. At this year's conference, Professor Xiaohui Zhang's team from Peking University People's Hospital performed outstandingly, with four studies selected for oral presentation, and one study awarded the YoungEHA Best Abstract Award, making it one of the four global award-winning studies of the year and the only one from China to receive this honor. This achievement not only highlights the team's exceptional strength but also showcases the potential and capabilities of Chinese researchers. "Oncology Frontier - Hematology Frontier" specially invited Professor Xiaohui Zhang and his team members for a roundtable discussion to share their research findings, covering non-invasive diagnostic techniques, mechanisms of CAR-T cell therapy toxicity in relapsed/refractory T-cell leukemia, prognosis models for mixed phenotype acute leukemia (MPAL), and innovative clinical research in immune thrombocytopenia (ITP).
Professor Enqiang Chen: Identification and Management of Cholestatic Drug-Induced Liver Injury Related to Antitumor Drugs

Professor Enqiang Chen: Identification and Management of Cholestatic Drug-Induced Liver Injury Related to Antitumor Drugs

Cholestatic drug-induced liver injury (DILI) is a drug-induced condition characterized primarily or prominently by intrahepatic cholestasis, featuring clinical, biochemical, and histopathological evidence. It is a relatively common and serious adverse drug reaction that can lead to acute liver failure and even death, affecting the clinical application of medications. In recent years, significant breakthroughs in targeted and immunotherapy for cancer have markedly improved the prognosis and survival of patients with malignancies. However, liver injury caused by antitumor drugs, particularly cholestatic DILI, has become a major clinical concern. Recently, at the 8th International Forum on Drug-Induced Liver Injury and the 9th National Conference on Drug-Induced Liver Injury, Professor Enqiang Chen from West China Hospital of Sichuan University, delivered an outstanding report on cholestatic DILI, which is summarized below for our readers.
ASCO 2024丨New Research Highlights on Cholangiocarcinoma: Mixed Results for Targeted and Immunotherapy

ASCO 2024丨New Research Highlights on Cholangiocarcinoma: Mixed Results for Targeted and Immunotherapy

Cholangiocarcinoma (BTC), often called the "silent killer," constitutes less than 1% of adult cancers and has a poor prognosis with limited patient survival. Current treatments primarily involve surgery and chemotherapy, but their efficacy is limited. Recently, various targeted drugs and immune checkpoint inhibitors (ICIs) have provided new therapeutic options for BTC patients. The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting presented several new drug research updates on BTC. Here, we summarize three oral presentation studies.
Xinghai Forum: I CAME, I SAW, I-SPY—Exploring the Highlights of the I-SPY 2.2 Study and Its Clinical Practice Value

Xinghai Forum: I CAME, I SAW, I-SPY—Exploring the Highlights of the I-SPY 2.2 Study and Its Clinical Practice Value

From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was grandly held, bringing together cutting-edge developments from home and abroad. At the previous ASCO conference, the results of the I-SPY 2.2 study were released, providing new insights into optimizing neoadjuvant treatment plans for breast cancer, exploring the application of immune checkpoint inhibitors combined with antibody-drug conjugates (ADCs), and investigating step-up and step-down treatment strategies. At the Xinghai Forum, Oncology Frontier invited Professor Shu Wang from Peking University People's Hospital, Professor Zhigang Yu from Qilu Hospital of Shandong University, Professor Haibo Wang from The Affiliated Hospital of Qingdao University, and Professor Guangyu Liu from Fudan University Shanghai Cancer Center to discuss the highlights of the I-SPY 2.2 study and its reference value for clinical practice.
EHA China’s Voice : Professor Jia Wei’s Team on UBE2Q1’s Impact on Antigen Presentation in AML and Clinical Prognosis and Molecular Characteristics

EHA China’s Voice : Professor Jia Wei’s Team on UBE2Q1’s Impact on Antigen Presentation in AML and Clinical Prognosis and Molecular Characteristics

The 29th Annual Congress of the European Hematology Association (EHA) was held grandly in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, Professor Jia Wei's team from Tongji Hospital, Huazhong University of Science and Technology had multiple studies selected for poster or e-poster presentations. This issue focuses on two studies in the field of myeloid tumors. One study (P487), conducted in collaboration with Associate Professor Yu Xiaoxuan from Nanjing University of Chinese Medicine, explores the relationship between UBE2Q1 and AML prognosis and its mechanism of affecting antigen presentation in AML. The other study (P1885) investigates the clinical prognosis and molecular characteristics of MDS patients with ASXL1 mutations.
15th International T-Cell Lymphoma Forum丨Professor Wenyu Shi and Dr. Yi Miao: Application of EASIX in Predicting Survival of T/NK-LA HLH Patients

15th International T-Cell Lymphoma Forum丨Professor Wenyu Shi and Dr. Yi Miao: Application of EASIX in Predicting Survival of T/NK-LA HLH Patients

A research study led by Professor Wenyu Shi from the Affiliated Hospital of Nantong University and Dr. Yi Miao from The First Affiliated Hospital with Nanjing Medical University (Jiangsu Provincial Hospital), under the Jiangsu Lymphoma Collaboration Group and the Jiangsu HLH Working Group, was selected for an oral presentation. This study is the first to show that the Endothelial Activation and Stress Index (EASIX) is a reliable predictor of outcomes in patients with T/NK cell lymphoma-associated hemophagocytic lymphohistiocytosis (T/NK-LA HLH).The 15th International T-Cell Lymphoma Forum successfully took place from June 6 to 8, 2024, in San Diego, USA. This forum brought together top clinicians, researchers, and distinguished representatives from the medical field worldwide, aiming to advance the research and innovation in T-cell lymphoma, ultimately improving patient survival and well-being.  "Oncology Frontier - Hematology Frontier" invited Professor Shi and Dr. Miao for an interview to share and interpret the study's content and significance.
Immune Reconstitution Following CD7 CAR-T Therapy for Relapsed/Refractory Acute T-cell Lymphoblastic Leukemia/T-cell Lymphoblastic Lymphoma

Immune Reconstitution Following CD7 CAR-T Therapy for Relapsed/Refractory Acute T-cell Lymphoblastic Leukemia/T-cell Lymphoblastic Lymphoma

From June 13 to 16, 2024, the 29th Annual Congress of the European Hematology Association (EHA) was held in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world every year to share and discuss innovative ideas and the latest scientific and clinical research results in hematology. At this year's EHA meeting, a study (S119) by Professor Xian Zhang from Beijing Lu Daopei Hospital was selected for oral presentation. The study explored immune reconstitution in R/R T-ALL/LBL patients following CD7 CAR-T therapy. “Oncology Frontier - Hematology Frontier” interviewed Professor Xian Zhang to introduce and interpret the study's content and topics related to the treatment of R/R T-ALL/LBL.
EHA in 5 Minutes | Professor Huanling Zhu: SUSTRENIM Trial— Observational Study on Sustained Deep Molecular Response and Treatment-Free Remission

EHA in 5 Minutes | Professor Huanling Zhu: SUSTRENIM Trial— Observational Study on Sustained Deep Molecular Response and Treatment-Free Remission

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international event in the field of hematology in Europe, this conference attracts numerous renowned experts and scholars from around the world to share and discuss innovative concepts, the latest scientific research, and clinical study results in hematology. To gain a deeper understanding of the latest research in Chronic Myeloid Leukemia (CML), "Oncology Frontier - Hematology Frontier" has invited Professor Huanling Zhu from West China Hospital of Sichuan University, to provide an in-depth interpretation.
ASCO 2024丨mRNA-4157 Vaccine Shows Long-Term Survival Benefits in Melanoma Treatment

ASCO 2024丨mRNA-4157 Vaccine Shows Long-Term Survival Benefits in Melanoma Treatment

mRNA cancer vaccines are an emerging cancer treatment strategy that uses mRNA technology to encode tumor-associated antigens, stimulating the patient's immune system to fight cancer cells. With the successful application of mRNA technology in vaccine development, its role in cancer treatment is gaining increasing attention. mRNA-4157 is a novel personalized cancer vaccine that has shown promising efficacy in clinical trials. In the phase II KEYNOTE-942 study, mRNA-4157 combined with pembrolizumab extended relapse-free survival (RFS) for high-risk melanoma patients compared to pembrolizumab alone. At this year's ASCO meeting, the study presented updated 3-year follow-up data. Oncology Frontier has compiled and summarized the findings for our readers.
ASCO 2024丨Impact of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

ASCO 2024丨Impact of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 31 to June 4. Multiple research advancements in urologic oncology were presented, including the SWOG S1600 study results shared by Dr. Jill Hamilton-Reeves. This study explored the impact of immune-enhancing nutrition on the outcomes of radical cystectomy. Oncology Frontier has compiled and summarized the relevant content for our readers.